7 results on '"Suchowersky O"'
Search Results
2. Degradation of stored movement representations in the Parkinsonian brain and the impact of levodopa.
- Author
-
D'Andrea JN, Haffenden AM, Furtado S, Suchowersky O, and Goodyear BG
- Subjects
- Aged, Analysis of Variance, Antiparkinson Agents therapeutic use, Brain blood supply, Female, Humans, Imaging, Three-Dimensional, Levodopa therapeutic use, Magnetic Resonance Imaging, Male, Middle Aged, Oxygen blood, Parkinsonian Disorders drug therapy, Photic Stimulation, Reaction Time drug effects, Severity of Illness Index, Antiparkinson Agents pharmacology, Brain drug effects, Levodopa pharmacology, Movement drug effects, Parkinsonian Disorders pathology
- Abstract
Parkinson's disease (PD) results from the depletion of dopamine and other neurotransmitters within the basal ganglia, and is typically characterized by motor impairment (e.g., bradykinesia) and difficulty initiating voluntary movements. Difficulty initiating a movement may result from a deficit in accessing or executing a stored representation of the movement, or having to create a new representation each time a movement is required. To date, it is unclear which may be responsible for movement initiation impairments observed in PD. In this study, we used functional magnetic resonance imaging and a task in which participants passively viewed familiar and unfamiliar graspable objects, with no confounding motor task component. Our results show that the brains of PD patients implicitly analyze familiar graspable objects as if the brain has little or no motor experience with the objects. This was observed as a lack of differential activity within brain regions associated with stored movement representations for familiar objects relative to unfamiliar objects, as well as significantly greater activity for familiar objects when off levodopa relative to on medication. Symptom severity modulated this activity difference within the basal ganglia. Levodopa appears to normalize brain activity, but its effect may be one of attenuation of brain hyperactivity within the basal ganglia network, which is responsible for controlling motor behavior and the integration of visuomotor information. Overall, this study demonstrates that difficulty initiating voluntary movements experienced by PD patients may be the result of degradation in stored representations responsible for the movement., (Copyright © 2013 Elsevier Ltd. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
3. Non-motor symptoms and parkinsonism.
- Author
-
Suchowersky O
- Subjects
- Female, Humans, Male, Attention Deficit Disorder with Hyperactivity etiology, Olfaction Disorders etiology, Parkinson Disease complications, Parkinsonian Disorders complications, Sleep Wake Disorders etiology, Urination Disorders etiology
- Published
- 2013
- Full Text
- View/download PDF
4. Neuronal Intranuclear Inclusion Disease presenting as juvenile Parkinsonism.
- Author
-
Wiltshire KM, Dunham C, Reid S, Auer RN, and Suchowersky O
- Subjects
- Age of Onset, Antigens, CD metabolism, Biopsy methods, Diagnosis, Diagnosis, Differential, Humans, Intranuclear Inclusion Bodies metabolism, Ki-67 Antigen metabolism, Male, Nerve Tissue Proteins metabolism, Neurodegenerative Diseases metabolism, Neurodegenerative Diseases physiopathology, Ubiquitin metabolism, Young Adult, Intranuclear Inclusion Bodies pathology, Neurodegenerative Diseases diagnosis, Parkinsonian Disorders physiopathology
- Abstract
Background: Diagnostic considerations for juvenile onset Parkinsonism (onset at < 21 years of age) include juvenile Huntington disease, Wilson disease, dentatorubral-pallidoluysian atrophy (DRPLA), storage diseases, and mitochondrial cytopathies. Neuronal Intranuclear Inclusion Disease (NIID) must also be considered., Case Report: We present a case of juvenile onset NIID with a predominantly Parkinsonian presentation, followed later by corticospinal, cerebellar, and lower motor neuron symptoms., Conclusion: Diagnosis of NIID can be made antemortem through rectal biopsy, however it was missed in this case. Rectal biopsy should be performed in all suspected cases, reviewed by an experienced neuropathologist and repeated if the suspicion for NIID is high. Pathologically, SUMO-1 immunohistochemistry appears to reliably label the neuronal inclusions and abnormal SUMOylation may play a part in the pathogenesis.
- Published
- 2010
- Full Text
- View/download PDF
5. Parkinsonian deficits in context-dependent regulation of standing postural control.
- Author
-
Brown LA, Doan JB, Whishaw IQ, and Suchowersky O
- Subjects
- Adaptation, Physiological physiology, Aged, Aged, 80 and over, Case-Control Studies, Humans, Middle Aged, Multivariate Analysis, Pressure, Substance Withdrawal Syndrome physiopathology, Torque, Parkinsonian Disorders physiopathology, Postural Balance physiology, Posture physiology
- Abstract
This study explored whether patients with Parkinson's disease alter the regulation of upright standing according to constraints imposed by the environmental context. The provision of context-dependent adaptations was inferred from the presence of adjustments to standing postural control that would serve to reduce fall risk when balance was challenged by a threatening environmental context. Participants were asked to stand as still as possible in two environmental context conditions that differed in the level of imposed postural threat: LOW threat and HIGH threat. Eight levodopa dependent patients with Parkinson's disease (PD) and eight age-matched control subjects (CTRL) provided the subject sample. PD patients were tested following a 12-h withdrawal of anti-Parkinsonian medications and approximately 1h post-medication. The CTRL group showed altered postural control in the HIGH threat condition, in a manner that was indicative of appropriate context-dependent regulation of standing. PD patients, in the non-medicated or medicated states, did not modify stance regulation when the environmental context heightened postural threat. Our results extend the current understanding of Parkinsonian deficits in the context-dependent regulation of postural control to include upright standing.
- Published
- 2007
- Full Text
- View/download PDF
6. BDNF genetic variants are associated with onset age of familial Parkinson disease: GenePD Study.
- Author
-
Karamohamed S, Latourelle JC, Racette BA, Perlmutter JS, Wooten GF, Lew M, Klein C, Shill H, Golbe LI, Mark MH, Guttman M, Nicholson G, Wilk JB, Saint-Hilaire M, DeStefano AL, Prakash R, Tobin S, Williamson J, Suchowersky O, Labell N, Growdon BN, Singer C, Watts R, Goldwurm S, Pezzoli G, Baker KB, Giroux ML, Pramstaller PP, Burn DJ, Chinnery P, Sherman S, Vieregge P, Litvan I, Gusella JF, Myers RH, and Parsian A
- Subjects
- Age of Onset, DNA Mutational Analysis, Family Health, Gene Frequency, Genetic Testing, Haplotypes genetics, Homozygote, Models, Statistical, Parkinsonian Disorders epidemiology, Polymorphism, Single Nucleotide genetics, Risk Factors, Brain-Derived Neurotrophic Factor genetics, Genetic Predisposition to Disease genetics, Genetic Variation genetics, Parkinsonian Disorders genetics, Polymorphism, Genetic genetics
- Abstract
Brain-derived neurotrophic factor (BDNF) stimulates neuronal growth and protects nigral dopamine neurons in animal models of Parkinson disease (PD). Therefore, BDNF is a candidate gene for PD. The authors investigated five single-nucleotide polymorphisms in 597 cases of familial PD. Homozygosity for the rare allele of the functional BDNF G196A (Val66Met) variant was associated with a 5.3-year older onset age (p = 0.0001). These findings suggest that BDNF may influence PD onset age.
- Published
- 2005
- Full Text
- View/download PDF
7. Profile of families with parkinsonism-predominant spinocerebellar ataxia type 2 (SCA2).
- Author
-
Furtado S, Payami H, Lockhart PJ, Hanson M, Nutt JG, Singleton AA, Singleton A, Bower J, Utti RJ, Bird TD, de la Fuente-Fernandez R, Tsuboi Y, Klimek ML, Suchowersky O, Hardy J, Calne DB, Wszolek ZK, Farrer M, Gwinn-Hardy K, and Stoessl AJ
- Subjects
- Antiparkinson Agents therapeutic use, Brain blood supply, Brain metabolism, Brain pathology, Corpus Striatum blood supply, Corpus Striatum metabolism, Dopamine Plasma Membrane Transport Proteins, Dystonia epidemiology, Humans, Levodopa therapeutic use, Magnetic Resonance Imaging, Membrane Glycoproteins metabolism, Membrane Transport Proteins metabolism, Nerve Tissue Proteins metabolism, Parkinsonian Disorders drug therapy, Parkinsonian Disorders epidemiology, Posture, Spinocerebellar Ataxias drug therapy, Spinocerebellar Ataxias epidemiology, Tomography, Emission-Computed, Tomography, Emission-Computed, Single-Photon, Tremor drug therapy, Tremor epidemiology, Parkinsonian Disorders genetics, Spinocerebellar Ataxias genetics
- Abstract
Spinocerebellar ataxia type 2 (SCA2) has been recognized recently as an uncommon cause of parkinsonism, an alternate presentation to the typical cerebellar disorder. This research review summarizes the existing literature on parkinsonism-predominant presentation SCA2 and presents new clinical cases of patients with this condition. Various phenotypes are noted in this subtype of SCA2, including parkinsonism indistinguishable from idiopathic Parkinson's disease (PD), parkinsonism plus ataxia, motor neuron disease, and postural tremor. In several kindreds with multiple affected family members, the SCA2 expansion segregated with disease; in addition, several single cases of parkinsonism with and without a family history are also described. The number of repeats in symptomatic patients ranged from 33 to 43. Interruption of the CAG repeat with CAA, CGG, or CCG was found in some individuals, possibly stabilizing the repeat structure and accounting for the relative stability of the repeat size across generations in some families; allele length is not necessarily indicative of trinucleotide repeat architecture. Positron emission tomography scanning in one family showed reduced fluorodopa uptake and normal to increased raclopride binding with a rostrocaudal gradient similar to that found in idiopathic PD. This review emphasizes the importance of testing for SCA2 in patients with parkinsonism and a family history of neurodegenerative disorders. Testing for SCA2 is also important in studies of inherited parkinsonism., (Copyright 2004 Movement Disorder Society)
- Published
- 2004
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.